1. ãªãã¢ãžã¢äººã«äººæ°ã
ã¢ãžã¢ã®æååã«ãããŠãé¡ãç¹ã«é¡ïŒåé éšïŒã®åœ¢ç¶ã¯ãå人ã®å°è±¡ã瀟äŒçãªè©äŸ¡ãããã«ã¯éå¢ã«ãŸã§éèŠãªåœ±é¿ãäžãããšèããããŠããŸãã
å ·äœçã«ã¯ãè»çµç¹ã®æ¬ æã骚ã®äžèŠåãªå¹åžããªããå·Šå³å¯Ÿç§°ã§èª¿åããšãããµã£ãããšããé¡ã®åœ¢ç¶ã¯ãåãªãçŸããã®è±¡åŸŽã«ãšã©ãŸãããç¹æ ããªãŒããŒã·ããã®èœåããããŠç€ŸäŒçãªæåã瀺ããŠãããšå€ãããä¿¡ããããŠããŸãïŒChou 2017ïŒã
è§£ååŠçã«èŠãŠããé¡ã®èšãã¿ã¯é¡å šäœã®ãã©ã³ã¹ãšèª¿åã«ãšã£ãŠéåžžã«éèŠãªåœ¹å²ãæãããŠããŸããç¹ã«åŽé¢ãæãããèŠãéã®ã·ã«ãšããã«ãããŠãããã®ãªããããã«åžç¶ãæããªããããªé¡ã¯ãé¡å šäœã«ç«äœæãäžãã人ã®é¡ãšäžè¬çãªã€ã¡ãŒãžã«å€§ããªé åãå ãããšãããŠããŸãïŒChou 2017ïŒã
ã¢ãžã¢äººã¯éªšæ Œçã«é¡ãå¹³åŠã§ãã£ãããå¹åžãç®ç«ã¡ãããåŸåããããããããäžžã¿ã®ãã女æ§ãããè¥ã ããå€èŠãæ±ãã声ãå€ããããŸãããã®ãããªæåçèæ¯ãšçŸæèãããé¡ã®èŒªéãæ»ããã«æŽããè¥ã ããé åçãªå€èŠãåŸãããã®ææ®µãšããŠãé¡ãžã®èªå®¶èèªæ³šå ¥ïŒèèªç§»æ€ïŒãã¢ãžã¢äººã®éã§æ¥µããŠé«ã人æ°ãéããŠããã®ã§ãïŒChou 2017ïŒã
2. MAFTãã¯ããã¯
MAFTïŒMicro-autologous fat transplantationïŒãã€ã¯ãèªå®¶èèªç§»æ€ïŒã¯ãåŸæ¥ã®èèªæ³šå ¥ã«ãããçççã®äœããããããïŒçµç¯ïŒã®åœ¢æãšãã£ãå䜵çãå æããäºæž¬å¯èœã§äžè²«ããçµæãåŸãããã«éçºããã粟å¯ãªæ³šå ¥æè¡ã§ãïŒChou 2017ïŒã
MAFTã®åºæ¬æŠå¿µãšå°çšæ©åš
éå»ã®çµç¹åŠçç ç©¶ïŒCarpanedaãïŒã«ãããç§»æ€ãããèèªããŒã»ã«ïŒå¡ïŒã®ååŸã2 mmïŒããªã¡ãŒãã«ïŒãè¶ ãããšãåšå²ããã®è¡æµãæ é€ã®æµžéãå±ãããäžå¿éšã®èèªçްèã壿»ããŠããŸãããšã瀺ãããŠããŸãïŒChou 2017ïŒã
ãã®äžå¿å£æ»ãé²ããããMAFTã®æŠå¿µã§ã¯1åã®æ³šå ¥éïŒããŒã»ã«ãµã€ãºïŒã1/100 mL (0.01 mL) æªæºã«ä¿ã€ããšãåºæ¬ãšããŠããŸããäœç©0.01 mLã®çç¶ã®èèªããŒã»ã«ã¯ãååŸãçŽ1.3 mmïŒããªã¡ãŒãã«ïŒãšãªããããè¡æµãè¡ãæž¡ããããçåçãé£èºçã«åäžããŸãïŒChou 2017ïŒã
ãã®æ¥µããŠåŸ®éãªæ³šå ¥ãæ£ç¢ºãã€é£ç¶çã«è¡ããããMAFT-GUNãšããå°çšã®ç¹èš±ååŸæžã¿ç²Ÿå¯æ©åšã䜿çšãããŸãããã®åšå ·ãçšããããšã§ãå€ç§å»ã¯1/60ã1/90ã1/120ã1/150ã1/180ãããã³1/240 mLãšãã£ã埮å°ãªåäœã§èèªã®æ³šå ¥éãæ£ç¢ºã«å¶åŸ¡ããäžè²«ããŠåŸ®å°ç§»æ€ãè¡ãããšãå¯èœãšãªããŸãïŒChou 2017ïŒã
é¡ãžã®3å±€æ³šå ¥ã¢ãããŒã
é¡ãžã®MAFTã§ã¯ãè§£ååŠçæ§é ã«åºã¥ãã以äžã®3ã€ã®ç°ãªãå±€ã«èèªãæ éã«åæ£ãããŠæ³šå ¥ããŸãïŒChou 2017ïŒã
- æ·±ãå±€ïŒåé çã®åŸãã»åé 骚ã®éªšèäžïŒïŒ MAFT-GUNã®ãã€ã€ã«ã120ïŒ1åã®æ³šå ¥é 1/120 mL = 0.0083 mLïŒã«èšå®ããåé 骚ã®éªšèã®äžãæ»ãããããã«ããŠæç¶ã«èèªãé 眮ããŸãããã®å±€ã«ã¯éåžž5ã10 mLïŒããªãªããã«ïŒã®èèªãç§»æ€ãããé¡ã®åºæ¬çãªããªã¥ãŒã ãšåå°ãäœããŸãïŒChou 2017ïŒã
- äžéå±€ïŒåé çå ïŒïŒ ã«ãã¥ãŒã¬ãå°ãåŸããŠåé çã®çèå ã«é²ããŸããçèå ã¯è¡æµãéåžžã«è±å¯ã§ãããããç§»æ€ãããèèªçްèã«è¯å¥œãªè¡æ¶²äŸçµŠãæäŸãããŸãããã®å±€ã«ãéåžž5ã10 mLïŒããªãªããã«ïŒã®èèªãç§»æ€ãããŸãïŒChou 2017ïŒã
- æµ ãå±€ïŒç®äžå±€ã»çç®ãšåé çã®éïŒïŒ é¡ã®ç®èã¯é¡ã®äžã§æãåããçç®ããåé çã«åãã£ãŠæšªæ¹åã«èµ°ãäžéïŒçµåçµç¹ïŒãå¯ã«ååšããŠããŸãããã®ãããäžåºŠã«å€§éã®èèªãç§»æ€ããããšã¯å°é£ã§ããããã®å±€ãžã®æ³šå ¥éã¯éåžž3ã5 mLïŒããªãªããã«ïŒä»¥äžã«ãšã©ããããŸãã衚é¢ã®æ»ããããæŽãã圹å²ãæãããŸãïŒChou 2017ïŒã
æè¡å®çžŸãšæ£è ã®æºè¶³åºŠ
178äººã®æ£è ïŒå¥³æ§167人ãç·æ§11人ãå¹³å幎霢47.7æ³ïŒã察象ãšããç ç©¶ã§ã¯ãèèªã®æ¡åããç§»æ€ãŸã§ã®MAFTæé å šäœã«ããã£ãå¹³åæéã¯52åã§ããïŒChou 2017ïŒã
é¡ãžã®å¹³åæ³šå ¥éã¯10.2 mLïŒããªãªããã«ïŒã§ãããäžéšã®æ£è ïŒ12.6%ã22/178人ïŒã¯ãããè±ããªãµããã¿ãæ±ããŠè¡åŸ4ã6ã¶æã«2åç®ã®ã¿ããã¢ããæè¡ãåããŸããïŒChou 2017ïŒã
å¹³å34ã¶æïŒ8ã68ã¶æïŒã®é·æè¿œè·¡èª¿æ»ã®çµæãç¥çµè¡ç®¡ã®æå·ãç®èã®å£æ»ãè¿çãçµç¯åœ¢æãç·ç¶åãç³ç°åãé察称æ§ãªã©ã®é倧ãªå䜵çã¯äžåèšé²ãããŸããã§ããïŒChou 2017ïŒã
æçµçãªæ£è ã«ããæºè¶³åºŠè©äŸ¡ã§ã¯ã1åã®æœè¡ãåããæ£è ã®83.1%ãè¯å¥œãªçµæãåŸããšåçïŒ53.2%ãæºè¶³ã27.5%ãéåžžã«æºè¶³ïŒããŸãããããã«2åã®æœè¡ãåããæ£è ã§ã¯ã100%ïŒ86.4%ãéåžžã«æºè¶³ã13.6%ãæºè¶³ïŒãšããæ¥µããŠé«ãæºè¶³åºŠã確èªãããŠããŸãïŒChou 2017ïŒã
3. å®ççã¡ã¿åæ
é¡é¢ãžã®èªå®¶èèªæ³šå ¥ã«ãããŠãæ³šå ¥ãããèèªãæçµçã«ã©ã®çšåºŠççãããïŒå®ççïŒvolume retention rateïŒã¯ãå€ç§å»ãšæ£è ã®åæ¹ã«ãšã£ãŠæãé¢å¿ã®é«ãããŒãã§ãããããŸã§å»åž«ã®çµéšåã«åºã¥ãããšãå€ãã£ãå®ççã«ã€ããŠã客芳çãªç»åæè¡ãçšããå®éçãªã¡ã¿åæãè¡ãããŠããŸãã
å¹³åå®ççãšçµæçå€å
é¡é¢ã«èèªæ³šå ¥ãåãã1011äººã®æ£è ãå«ã27ã®ç ç©¶ã察象ãšããã¡ã¿åæã«ãããšãé¡é¢èèªç§»æ€ã®å šäœçãªããŒã«ãããå¹³åå®ççã¯47%ïŒ95% ä¿¡é Œåºé 41â53%ïŒã§ããããšã瀺ãããŸããïŒLv 2020ïŒã
åç ç©¶ã§å ±åãããå®ççã¯26%ãã83%ãŸã§ãšå¹ åºãã°ãã€ããããã远跡æéã¯å¹³åããŠ3ã24ã¶æã§ããïŒLv 2020ïŒã
å®ççã¯æéã®çµéãšãšãã«åçã«å€åããŸããè¡åŸ3ã¶æã6ã¶æã12ã¶æãšçµéããã«ã€ããŠå®ççã¯åŸã ã«äœäžããäœç©ã®æå€§ã®æžå°ã¯è¡åŸæåã®3ã¶æéã«çºçããããšãæããã«ãªã£ãŠããŸãïŒLv 2020ïŒã
ãã®åæã®äœç©æžå°ã¯ãæ°Žåã®åžåãçåã§ããªãã£ã现èã®åžåã«ãããã®ãšèããããŠããŸãããã®åŸãçåããæçèèªçްèãååã»å¢æ®ããããšã§äœç©ãå®å®ããŠãããšæšæž¬ãããŠããŸãïŒLv 2020ïŒã
å®ççã«åœ±é¿ãäžããèŠå ãšå䜵ç
ãã®ã¡ã¿åæã§ã¯ãå®ççã«åœ±é¿ãäžããå¯èœæ§ã®ããæ§ã ãªèšåºçèŠå ã«ã€ããŠããµãã°ã«ãŒãåæãè¡ãããŠããŸãïŒLv 2020ïŒã
- æ³šå ¥åæ°ïŒ ååã®æ³šå ¥ïŒãã©ã€ããªãŒïŒãããã2åç®ã®èèªæ³šå ¥ïŒã»ã«ã³ããªãŒïŒã®æ¹ãé«ãå®ççã瀺ãæç¢ºãªåŸåã確èªãããŸãããããã¯ãååã®ç§»æ€ã«ãã£ãŠã¬ã·ããšã³ãéšäœã®çµç¹ãè±ãã«ãªããè¡æµã®åå°ã圢æããããããšèããããŸãïŒLv 2020ïŒã
- èèªåŠçæ¹æ³ïŒ æ¡åããèèªã®åŠçã«ãããŠãé å¿åé¢ããéïŒãã£ã«ãã¬ãŒã·ã§ã³ïŒãçšããæ¹æ³ã¯ãåãªãæ²æ®¿æ³ïŒã»ãã£ã¡ã³ããŒã·ã§ã³ïŒãšæ¯èŒããŠãããäžè²«ããè¯å¥œãªçççµæãããããå¯èœæ§ã瀺åãããŠããŸãïŒLv 2020ïŒã
- æ£è ã®é©å¿çïŒ çŽç²ãªçŸå®¹ç®çã®å¢å€§ããããå 倩æ§ã®é¡é¢å€åœ¢ãæã€æ£è ã«ãããŠãããé«ãå®ççã瀺ãåŸåãèŠãããŸãããããã¯ãå 倩æ§å€åœ¢ã®è»çµç¹ããç§»æ€èèªã«å¯ŸããŠæ é€ãäŸçµŠããããç·©ãè¶³å ŽïŒã¹ãã£ãã©ãŒã«ãïŒãæäŸã§ãããããšæšæž¬ãããŠããŸãïŒLv 2020ïŒã
- èèªã®æ¡åéšäœïŒ è ¹éšãå€§è ¿éšãªã©ãèèªãæ¡åãããããŒéšäœã®éãã«ãã£ãŠãå®ççã«ææãªå·®ã¯èªããããŸããã§ããïŒLv 2020ïŒã
- äœç©æž¬å®æ¹æ³ã®åœ±é¿ïŒ CTã¹ãã£ã³ãçšããæž¬å®ã¯ã3Dã¹ãã£ã³ãçšããæž¬å®ãšæ¯èŒããŠå®ççãé倧è©äŸ¡ãããïŒããé«ãç®åºãããïŒå¯èœæ§ãããããšã倿ããŠããŸãïŒLv 2020ïŒã
ãªãã察象ãšãªã£ã1011äººã®æ£è ã®ãã¡ãå䜵çãçµéšããã®ã¯ããã2.8%ïŒ28人ïŒã§ãããææçãäžèŠåãªå¹åžãé察称æ§ãéå°è£æ£ãªã©ã®æ¯èŒç軜床ãªãã®ãäžå¿ã§ããïŒLv 2020ïŒã
4. ãã€ã¯ããã¡ããã»ãããã¡ãã䜿ãåã
çŸä»£ã®èèªæ³šå ¥ã«ãããŠã¯ãæ¡åããèèªããã®ãŸãŸæ³šå ¥ããã®ã§ã¯ãªããæ³šå ¥ããéšäœãç®çã«å¿ããŠèèªã®ç²åãµã€ãºïŒããŒã»ã«ãµã€ãºïŒã粟å¯ã«å å·¥ãã䜿ãåããã¢ãããŒããäž»æµãšãªã£ãŠããŸããããã«ãããèªç¶ãªããªã¥ãŒã ã®å埩ãšç®èã®åçãåæã«éæããããšãå¯èœã§ãã
ITR2ã«åºã¥ãåèèªã¿ã€ãã®ç¹æ§ãšé©çšéšäœ
æ°ããæšæºåæè¡ã§ããITR2ïŒInjectable Tissue Replacement and RegenerationïŒæ³šå ¥åçµç¹çœ®æã»åçïŒã§ã¯ãèèªã以äžã®3ã€ã®ã¿ã€ãã«åããé¡ã®è§£ååŠçã³ã³ããŒãã¡ã³ãã«é 眮ããŸãïŒCrowley 2021ïŒã
- ããªãã¡ããïŒMillifatïŒïŒ ããŒã»ã«ãµã€ãºã2ã2.4 mmïŒããªã¡ãŒãã«ïŒã®æ¯èŒç倧ããªèèªã®å¡ã§ããæ§é çãªãµããŒããå¿ èŠãªé åã«é©ããŠãããæ·±ãèèªã³ã³ããŒãã¡ã³ãã®çœ®æãã骚ã®äžã®å¢å€§ïŒãªã³ã¬ãŒã°ã©ããïŒãé垯ã®ãµããŒããåã®æ§é 圢æã«äœ¿çšãããŸãïŒCrowley 2021ïŒã
- ãã€ã¯ããã¡ããïŒMicrofatïŒïŒ ããŒã»ã«ãµã€ãºãçŽ1.0ã1.2 mmïŒããªã¡ãŒãã«ïŒã«çްããå å·¥ãããèèªã§ããé¡ã®çèããäžã«äœçœ®ããæµ ãç®äžèèªã³ã³ããŒãã¡ã³ãã®ããªã¥ãŒã æžå°ãè£ããããªãªãããã©ã€ã³ãå£åšãã®ãããªã©ã衚é¢ã®æ»ããããäœãããã«äœ¿çšãããŸãïŒCrowley 2021ïŒã
- ãããã¡ããïŒNanofatïŒïŒ èèªãç¹æ®ãªãã£ã«ã¿ãŒã«äœåºŠãéãããšã§ãæ©æ¢°çã«çްããä¹³åãããæ¶²ç¶ã®èèªã§ããããŒã»ã«ãµã€ãºã¯400ã800ãã¯ãã³ïŒãŸãã¯500ãã¯ãã³ïŒãŸã§åŸ®çްåãããŠããïŒCrowley 2021ïŒãå¥ã®ç ç©¶ã§ã¯100 ÎŒmïŒãã€ã¯ãã¡ãŒãã«ïŒæªæºãšãå ±åãããŠããŸãïŒWei 2017ïŒã
ãããã¡ããã«ããåçå»ç广
ãããã¡ããã¯ã现ããä¹³åãããéçšã§æçããèèªçްèã®å€ããç Žå£ãããŸããããã®ä»£ãããšããŠSVFïŒé質è¡ç®¡çްè矀ïŒãèèªç±æ¥å¹¹çްèïŒASCïŒã極ããŠè±å¯ã«å«ãŸããç¶æ ã«ãªããŸãïŒCrowley 2021ïŒããã®ãããããªã¥ãŒã ãåºããå å¡«å€ããšããŠã§ã¯ãªãããåçå»çããç®çãšããŠäœ¿çšãããŸãã
- ç®èã®è¥è¿ãïŒã¹ãã³ãªãžã¥ãããŒã·ã§ã³ïŒïŒ ãããã¡ããã¯éåžžã«æ»ãããªããã27ã²ãŒãžã®ãããªçްãéãçšããŠçç®å ãç®äžã«çŽæ¥æ³šå ¥ãããããã€ã¯ãããŒãã«ãçšããŠç®è衚é¢ã«å°å ¥ããããšãå¯èœã§ããããã«ããã现èããåæ³ãããæé·å åããµã€ãã«ã€ã³ãåããã³ã©ãŒã²ã³ã®çæãä¿ãããç®èã®è³ªæãåŒŸåæ§ãæ¯ç©Žã®ãµã€ãºãæ°Žåéãããã«ã¯å°ãããè²çŽ æ²çãé¡èã«æ¹åãããŸãïŒCrowley 2021ïŒïŒWei 2017ïŒã
- è¡ç®¡æ°çãšçççã®åäžïŒ ãããã¡ããã«å«ãŸããSVFã¯ãç§»æ€ãããåšå²ã®çµç¹ã«è¿ éãªè¡ç®¡æ°çïŒæ°ããè¡ç®¡ã®åœ¢æïŒãä¿ãåãããããŸããããªãã¡ããããã€ã¯ããã¡ãããšçµã¿åãããŠäœ¿çšããããšã§ãèèªç§»æ€çã®äžå¿éšãŸã§è¡æ¶²ãè¡ãæž¡ãããããªããç§»æ€ãããèèªçްèã®çåçïŒçççïŒãç·åçã«é«ããããšãã§ããŸãïŒWei 2017ïŒã
5. åè塿 ãªã¹ã¯
é¡é¢ãžã®èªå®¶èèªæ³šå ¥ã¯ãäžè¬çã«å®å šã§å¹æçãªæé ãšèŠãªãããŠããŸãããè§£ååŠçãªçè§£ã®æ¬ åŠãäžé©åãªæ³šå ¥æè¡ã«ãã£ãŠã誀ã£ãŠè¡ç®¡å ã«èèªãæ³šå ¥ãããå Žåãåè塿 ïŒArterial EmbolismïŒAEïŒãšããéåžžã«å£æ» çã§äžå¯éçãªå䜵çãåŒãèµ·ãããªã¹ã¯ããããŸãã
çºçç¶æ³ãšé«ãªã¹ã¯ãªæ³šå ¥éšäœ
èèªæ³šå ¥åŸã®åè塿 ã«é¢ãã61äººã®æ£è ïŒå¥³æ§53人ãç·æ§7人ããã©ã³ã¹ãžã§ã³ããŒ1人ãå¹³å幎霢33.56 ± 11.45æ³ïŒã察象ãšããã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã«ãããšãAEãæãé »ç¹ã«çºçããæ³šå ¥éšäœã¯ä»¥äžã®éãã§ãïŒMoellhoff 2023ïŒã
- çéïŒGlabellaïŒãŸãã¯è€æ°ã®é¡é¢é åïŒå26.2%ïŒ16/61人ïŒïŒMoellhoff 2023ïŒ
- ãããã¿ïŒTempleïŒïŒ16.4%ïŒ10/61人ïŒïŒMoellhoff 2023ïŒ
- é¡ïŒForeheadïŒïŒ14.8%ïŒ9/61人ïŒïŒMoellhoff 2023ïŒ
ãããã®å¡æ çäŸã«ãããèèªã®å¹³åæ³šå ¥éã¯ã21.5 ± 21.5 mlïŒããªãªããã«ïŒã§ããã0.5 mlãã70 mlãŸã§å¹ ããããŸããïŒMoellhoff 2023ïŒã
çç¶ãšç æ çç
塿 ã«ããçç¶ã®çºçŸã¯éåžžã«æ¥æ¿ã§ããã倧倿°ã®æ£è ïŒ66.0%ã33/50人ïŒã«ãããŠãæ³šå ¥äžãŸãã¯æ³šå ¥çŽåŸãã1æé以å ã«æåã®çç¶ãçŸããŸããïŒMoellhoff 2023ïŒã
æãå€ãå ±åãããçç¶ã¯ãèŠåäœäžãçŒçãªã©ã®ãèŠèŠçç¶ãïŒ41.4%ã24/58人ïŒã§ãããæ¬¡ãã§æèåªå€±ãç麻çºã倱èªçãªã©ã®ãç¥çµçç¶ãïŒ34.5%ã20/58人ïŒããŸãã¯èŠèŠãšç¥çµã®äž¡æ¹ã®çç¶ïŒ22.4%ã13/58人ïŒãç¶ããŸããïŒMoellhoff 2023ïŒã
é¡é¢ã®è¡æµã¯ãå é žåèç³»ãšå€é žåèç³»ã®æãè€éã«çµ¡ã¿åããè±å¯ãªå»åïŒãããã¯ãŒã¯ïŒã圢æããŠããŸããçéãé¡ãžã®æ³šå ¥æã«ãæ»è»äžåèãçŒçª©äžåèãªã©ã®å é žåèç³»ã®æã«èèªãçŽæ¥æ³šå ¥ãããããæ³šå ¥æã®é«ãå§åã«ãã£ãŠèèªã®ããŒã©ã¹ïŒå¡ïŒãéè¡æ§ã«æŒãæ»ããããããããšã§ã塿 ãçºçããŸãããŸããå€é žåèç³»ã®æã«æ³šå ¥ãããå Žåã§ããå»åãéããŠå é žåèç³»ãžãšå¡æ åãç§»åããããšããããŸãïŒMoellhoff 2023ïŒã
é倧ãªè»¢åž°ãšç®¡çã®éç
éå¡ããè¡ç®¡ã®åæã§ã¯ãçŒåèïŒOAïŒã®éå¡ã43.3%ïŒ26/60人ïŒãå倧è³åèãŸãã¯äžå€§è³åèãšãã£ã倧è³åèïŒCAïŒã®éå¡ã18.3%ïŒ11/60人ïŒããããŠOAãšCAã®äž¡æ¹ã®éå¡ã23.3%ïŒ14/60人ïŒã§ããïŒMoellhoff 2023ïŒã
ãããã®è»¢åž°ã¯æ¥µããŠæ·±å»ã§ãããæ£è ã®äººçã倧ããå·Šå³ããŸãã
- çŒåèïŒOAïŒã®éå¡ãèµ·ãããæ£è ã®100%ïŒ26/26人ïŒããæ°žä¹ çãªå€±æã«è³ããŸããïŒMoellhoff 2023ïŒã
- 倧è³åèïŒCAïŒã®éå¡ãèµ·ãããæ£è ã®å€§éšåïŒ80%ã8/10人ïŒãã麻çºãªã©ã®æ°žä¹ çãªç¥çµéå®³ãæ®ããŸããïŒMoellhoff 2023ïŒã
- OAãšCAã®äž¡æ¹ãéå¡ããæ£è ã®63.6%ïŒ7/11人ïŒã倱æãçµéšããŸããïŒMoellhoff 2023ïŒã
- ããã«ãèèªå¡æ ãåå ã§6äººã®æ£è ãæ»äº¡ããŠããŸãïŒMoellhoff 2023ïŒã
ãã¢ã«ãã³é žæ³šå ¥ã®éã§ããã°ããã¢ã«ããããŒãŒãšããæº¶è§£å€ïŒè§£æ¯å€ïŒã泚å°ããããšã§è¡æµãå埩ã§ããå¯èœæ§ããããŸãããèªå®¶èèªã«ã¯ãã®ãããªæº¶è§£å€ãååšããŸããããã®ãããä¿åçæ²»çãè¬ç©çæ³ãå€ç§çæžå§è¡ãªã©ãè¡ãããŸããã塿 ãèµ·ããå Žåã®æå¹æ§ã確ç«ãããæ²»çã¢ã«ãŽãªãºã ã¯ååšãããäºåŸã¯éåžžã«äžè¯ã§ãããããã£ãŠã塿 ããæ²»çãããã®ã§ã¯ãªãããäºé²ãããããšãäœãããéèŠãšãªããŸãïŒMoellhoff 2023ïŒã
6. å®å šãã€ã³ã
åè¿°ã®å€±æãè³åäžãšãã£ã壿» çãªåè塿 ãªã¹ã¯ãå®å šã«åé¿ããå®å šã«é¡ã®èèªæ³šå ¥ãè¡ãããã«ãå€ç§å»ã峿 Œã«éµå®ãã¹ãéèŠãªå®å šãã€ã³ãïŒäºé²çïŒããããŸãã
æ·±ãè§£ååŠçç¥èã®ç¿åŸ
å®å šæ§ãé«ããããã®çµ¶å¯Ÿæ¡ä»¶ã¯ãé¡é¢ã®è¡ç®¡ã®è§£ååŠçæ§é ãšããã®3次å çãªèµ°è¡ã³ãŒã¹ãå€ç§å»ãæ·±ãçè§£ããŠããããšã§ãïŒMoellhoff 2023ïŒã
é¡ãçéã«ã¯ãæ»è»äžåèãçŒçª©äžåèãšãã£ãå±éºãªè¡ç®¡ãååšããŸãããããã®è¡ç®¡ãé¿ããããã«ãæ³šå ¥ããçµç¹ã®å±€ïŒã¬ã€ã€ãŒïŒã深床ãããã³ã«ãã¥ãŒã¬ã®æ¹åãé©åã«èª¿æŽããå¿ èŠããããŸãïŒMoellhoff 2023ïŒã
é©åãªæ©åšã®éžæïŒééã«ãã¥ãŒã¬ã®äœ¿çšïŒ
è¡ç®¡å£ãçªãç Žããªã¹ã¯ãæå°éã«æãããããéå©ãªéïŒããŒãã«ïŒã§ã¯ãªããå ã®äžžãééïŒã«ãã¥ãŒã¬ïŒã䜿çšããããšãåŒ·ãæšå¥šãããŸãïŒMoellhoff 2023ïŒã
ãŸããéãã«ãã¥ãŒã¬ã®çŽåŸãµã€ãºãéèŠã§ããçŽåŸã倧ããïŒå€ªãïŒã«ãã¥ãŒã¬ã»ã©ãåèå£ã貫éããããã«å¿ èŠãªç©ççãªåãå¢å ããããã现ãéã䜿çšãããããè¡ç®¡å ã«å ¥ã蟌ãã§ããŸããªã¹ã¯ãäœããªããŸãããã®ããã18ã²ãŒãžä»¥äžã®å€ªãã®ã«ãã¥ãŒã¬ãå®å šãšãããŠããŸãïŒMoellhoff 2023ïŒã
å®éã«ãå®å šæ§ãé«ãè©äŸ¡ãããŠããMAFTã®ææ³ã«ãããŠããè¡ç®¡å æ³šå ¥ãç©ççã«é²ãããã«ãçŽåŸ1.2 mmïŒããªã¡ãŒãã«ïŒã®18Gééã«ãã¥ãŒã¬ã®äœ¿çšãæšæºãšãããŠããŸãïŒChou 2017ïŒã
å®å šãªæ³šå ¥ãã¯ããã¯ã®åŸ¹åº
æ©åšã®éžæã«å ããŠãå®éã®æ³šå ¥åäœã«ãããŠã以äžã®ååãå®ãå¿ èŠããããŸãã
- æ³šå ¥åã®åžåŒç¢ºèªïŒ èèªãæ³šå ¥ããçŽåã«ãã·ãªã³ãžã®ãã©ã³ãžã£ãŒã軜ãåŒããè¡æ¶²ãã·ãªã³ãžå ã«åŒããªããïŒéå ãè¡ç®¡å ã«å ¥ã£ãŠããªããïŒãå¿ ã確èªããããšãæšå¥šãããŸãïŒMoellhoff 2023ïŒã
- äœå§ã»åŸ®éã»éè¡æ§æ³šå ¥ïŒ èèªãæ³šå ¥ããéã¯ãã·ãªã³ãžã«åŒ·ãå§åãããããéåžžã«å°éã®èèªïŒã¢ãªã³ãŒãïŒããã«ãã¥ãŒã¬ãçµç¹ããåŒãæããªããïŒéè¡æ§ã«ïŒãã£ãããšæ³šå ¥ããå¿ èŠããããŸãïŒMoellhoff 2023ïŒã
- MAFT-GUNã®æŽ»çšã«ããå§åå¶åŸ¡ïŒ MAFT-GUNã®ãããªç²Ÿå¯æ©åšã䜿çšãããšã1åã®ããªã¬ãŒã§1/120 mL (0.0083 mL) ãšããæ¥µããŠåŸ®å°ãªèèªããäžè²«ããŠäœãå§åã§æŒãåºãããšãã§ããŸããããã«ãããæå泚å°ã§èµ·ãããã¡ãªãé«ãéè¡æ§å§åãã«ãã£ãŠãèèªã®å¡ãå é žåèç³»ã«æŒãæ»ãããŠããŸãå±éºæ§ãã»ãŒå®å šã«æé€ããããšãå¯èœã«ãªããŸãïŒChou 2017ïŒã
ãç§ã®å Žåã¯ã©ãã ããïŒããšæã£ãã
ç¡æã«ãŠã³ã»ãªã³ã°ãäºçŽãã
ç¡çãªå§èªã¯ããããŸããããæ°è»œã«ã©ããã
7. ãŸãšã
é¡ãžã®èèªæ³šå ¥ã¯ãã¢ãžã¢äººã«ãããŠé¡ã®ãã©ã³ã¹ãæŽãã調åã®ãšããè¥ã ããé åçãªå°è±¡ãäžããããã«éåžžã«äººæ°ã®ããçŸå®¹å»çã®æé ã§ãã
MAFTã®ãããªæŽç·ŽãããåŸ®éæ³šå ¥æè¡ã®ç»å Žããããªãã¡ããããã€ã¯ããã¡ããããããã¡ãããšãã£ãèèªã®ç²åãµã€ãºããšã®äœ¿ãåãïŒITR2ïŒã«ãããåãªãããªã¥ãŒã ã®å埩ã«ãšã©ãŸãããè質æ¹åãªã©ã®çµç¹ã®åçãåæã«éæããããšãå¯èœã«ãªã£ãŠããŸãã客芳çãªã¡ã¿åæã«ãã£ãŠããå®ççã¯å¹³åããŠ47%çšåºŠç¶æãããç¹ã«2åç®ã®æ³šå ¥ãé©åãªé å¿åé¢ã»ãéåŠçãè¡ãããšã§ãããå®å®ããé·æçãªçµæãæåŸ ã§ããããšã瀺ãããŠããŸãã
äžæ¹ã§ã誀ã£ãå±€ãè¡ç®¡å ãžã®æ³šå ¥ã¯ãæ°žä¹ çãªå€±æãè³åäžãææªã®å Žåã¯æ»äº¡ã«ã€ãªããèŽåœçãªåè塿 ïŒAEïŒãåŒãèµ·ããé倧ãªãªã¹ã¯ã䌎ããŸããèèªã«ã¯ãã¢ã«ãã³é žã®ãããªæº¶è§£å€ãååšããªããããå䜵çãèµ·ããŠããã®æ²»çã¯æ¥µããŠå°é£ã§ãããäºåŸã¯çµ¶æçã§ãã
ãããã£ãŠãé¡é¢ã®è©³çްãªè§£ååŠçç¥èã®çç¥ã18ã²ãŒãžä»¥äžã®ééã«ãã¥ãŒã¬ã®éžæãäœå§ã§ã®åŸ®éãã€éè¡æ§ã®æ³šå ¥ããããŠMAFT-GUNã®ãããªæ©åšã掻çšããæ£ç¢ºãªå¶åŸ¡ãšãã£ã峿 Œãªå®å šåºæºãéµå®ããããšãæ±ããããŸãããããã培åºããããšã§åããŠãæ£è ã®å®å šãå®å šã«å®ãã€ã€ãé·æçã§æé«ã¬ãã«ã®çŸççµæãåŒãåºãããšãã§ããã®ã§ãã
åèæç®
- Chou C, Liao H, Lin T, et al. Micro-Autologous Fat Transplantation for Forehead Volumization. Aesthetic Plastic Surgery. 2017 DOI
- Li X, Kubiak C, Yang X, et al. Forehead Fat Grafting: Asian Facial Contouring and Augmentation. Plastic & Reconstructive Surgery. 2019 DOI
- Kang G, Hsiao Y, Huang J, et al. Aesthetic Durable Forehead Contouring in Asians With Fat Grafting and Botulinum Toxin. Annals of Plastic Surgery. 2019 DOI
- Lv Q, Li Y, Fan Y, et al. Fat Grafting for Facial Rejuvenation: A Systematic Review and Meta-analysis of Volume Retention. Aesthetic Plastic Surgery. 2020 DOI
- Crowley J, Cohen S, Tirtho R, et al. Injectable Tissue Replacement and Regeneration (ITR2): A Comprehensive Review. Aesthetic Plastic Surgery. 2021 DOI
- Moellhoff N, Grawammer P, Giunta R, et al. Arterial Embolism After Autologous Fat Grafting to the Face: A Systematic Review. Aesthetic Plastic Surgery. 2023 DOI
ãã®èšäºãæžãã人
äžæ å®å å»åž«
Zetith Beauty Clinic é座ã»å€§éªã»çŠå²¡
æ¥æ¬åœå ããã³åœéåŠäŒã§ã®ç ç©¶çºè¡šå®çžŸãæã¡ãZetith Beauty Clinicå šäœã®æè¡æå°ã»æè²ã«ãæºãããè§£ååŠçæ ¹æ ã«åºã¥ãã粟å¯ãªçŸå®¹å»çãå°éãšããäžäººã²ãšãã®éªšæ Œãçµç¹ã«åãããèªç¶ãªä»äžããã远æ±ããŠããã